Conservative Management of MI risk in ACS

Original Title: Spontaneous MI after Non–ST-Segment Elevation Acute Coronary Syndrome Managed without Revascularization. The TRILOGY ACS Trial. Reference: Renato D. Lopes et al. J Am Coll Cardiol. 2016;67(11):1289-1297.

 

Patients admitted with acute coronary syndromes (ACS) and especially those managed conservatively without revascularization, are at high risk of a new spontaneous infarction. However, MI risk rate and predictors are unknown.

This study seeks to characterize spontaneous MI rate at 30 days in the TRILOGY ACS population admitted with non ST elevation ACS (TaRgeted platelet Inhibition to cLarify the Optimal strateGy to medically manage Acute Coronary Syndromes) that randomized patients to aspirin and clopidogrel vs. aspirin and prasugrel.

The study included 9294 patients with NSTEMI and unstable angina medically managed without revascularization.

A Cox risk model was used to determine MI predictors at 30 months and after model validation, researchers developed a calculator for model implementation.

Among the 9294 patients managed without revascularization strategy, there were 695 spontaneous infarctions over a median 17 months representing 94% of infarctions adjudicated in the study.

The strongest MI risk predictors were older age, NSTEMI vs. unstable angina as index event, diabetes, absence of angiography prior randomization and elevated creatinine values. The model had good discriminating capabilities and good calibration (c-index = 0.732), especially for patients with low and moderate risk of spontaneous MI.

Conclusion
Spontaneous ACS after medical management is frequent. Baseline statistics can be used to predict risk in this population. These findings provide information on the long term natural evolution of patients medically managed without revascularization.

More articles by this author

ACC-2025 Congress Second Day Key Studies

BHF PROTECT-TAVI (Kharbanda RK, Kennedy J, Dodd M, et al.)The largest randomized  trial carried out across 33 UK centers between 2020 and 2024, assessing...

ACC 2025 | FAME 3: FFR Guided PCI vs CABG 5 Year Outcomes.

Earlier studies comparing percutaneous coronary intervention (PCI) vs coronary artery bypass graft (CABG) have shown fewer events at long term for the surgical strategy.  However,...

CRABBIS Trial: Comparison of Different Provisional Stenting Sequences

Provisional stenting (PS) is the gold standard for percutaneous coronary intervention (PCI) in most patients with coronary bifurcation lesions (CBL). Moreover, recent studies such...

Andromeda Trial: Meta-Analysis of Drug Coated Balloon vs. DES in Small Vessel DeNovo Lesions

The use of coronary stents vs plain old balloon angioplasty (POBA), has allowed to reduce recoil and limiting flow dissection which were major limitation...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACC-2025 Congress Second Day Key Studies

BHF PROTECT-TAVI (Kharbanda RK, Kennedy J, Dodd M, et al.)The largest randomized  trial carried out across 33 UK centers between 2020 and 2024, assessing...

ACC 2025 | FAME 3: FFR Guided PCI vs CABG 5 Year Outcomes.

Earlier studies comparing percutaneous coronary intervention (PCI) vs coronary artery bypass graft (CABG) have shown fewer events at long term for the surgical strategy.  However,...

ACC 2025 | API-CAT: Reduced vs. Full Dose Extended Anticoagulation in Patients with Cancer Related VTE

The risk of cancer related recurrent venous thromboembolism (VTE) will drop over time, while bleeding risk will persist. At present, it is recommended we...